The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer

Anticancer Research

Volumn 26, Issue 6 C, 2006, Pages 4779-4784

  Rauvala, Marita ^a   Turpeenniemi Hujanen, Taina ^a   Puistola, Ulla ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Follow up; Gelatinases; Ovarian cancer; TIMP 1; TIMP 2

Indexed keywords

CYCLOPHOSPHAMIDE; GELATINASE A; GELATINASE B; PLATINUM; TAXANE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OVARY CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GELATINASES; HUMANS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 33845948559     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Santala M, Simojoki M, Risteli J, Risteli L and Kauppila A: Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer. Clin Cancer Res 5: 4091-4096, 1999.
2. Cracchiolo BM, Hanauske-Abel HM, Schwartz PE, Chambers JT, Holland B and Chambers SK: Procollagen-derived biomarkers in malignant ascites of ovarian cancer. Independent prognosticators for progression-free interval and survival. Gynecol Oncol 87: 24-33, 2002.
3. Woessner JF Jr: Matrix metalloproteinases and their inhibitors in connective tissue remodelling. FASEB J 5: 2145-2154, 1991.
4. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG and Quaranta V: Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5. Science 277: 225-228, 1997.
5. John A and Tuszynski G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7: 14-23, 2001.
6. Masson V, de la Ballina LR, Munaut C, Wielockx B, Jost M, Maillard C, Blacher S, Bajou K, Itoh T, Itohara S, Werb Z, Libert C, Foidart JM and Noel A: Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J 19: 234-236, 2005.
7. Ohno-Matsui K, Uetama T, Yoshida T, Hayano M, Itoh T, Morita I and Mochizuki M: Reduced retinal angiogenesis in MMP-2-deficient mice. Invest Ophthalmol Vis Sci 44: 5370-5375, 2003.
8. Jadhav U, Chigurupati S, Lakka SS and Mohanam S: Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells. Int J Oncol 25: 1407-1414 2004.
9. Gomez DE, Alonso DF, Yoshiji H and Thorgeirsson UP: Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74: 111-122, 1997.
10. Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA and Goldberg GI: SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 264: 17213-17221, 1989.
11. Stetler-Stevenson WG, Krutzsch HC and Liotta LA: Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 264: 17374-17378, 1989.
12. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA and Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane protease. J Biol Chem 270: 5331-5338, 1995.
13. Porter JF, Shen S and Denhardt DT: Tissue inhibitor of metalloproteinase-1 stimulates proliferation of human cancer cells by inhibiting a metalloproteinase. Br J Cancer 90: 463-470, 2004.
14. Zacchigna S, Zentilin L, Morini M, Dell'Eva R, Noonan DM, Albini A and Giacca M: AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther 11: 73-80, 2004.
15. Fernandez CA, Butterfield C, Jackson G and Moses MA: Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem 278: 40989-40995, 2003.
16. Rauvala M, Puistola U and Turpeenniemi-Hujanen T: Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 as a prognostic factor. Gynecol Oncol 99: 656-663, 2005.
17. Ylisirniö S, Höyhtyä M and Turpeenniemi-Hujanen T: Serum matrix metalloproteinases-2 and -9 and tissue inhibitor of metalloproteinases-1 and -2 in lung cancer; TIMP-1 as a prognostic marker. Anticancer Res 20: 1311-1316, 2000.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
19. Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A and Vermorken J: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 96: 487-488, 2004.
20. Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E and Puricelli L: Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 106: 745-751, 2003.
21. Waas ET, Wobbes T, Lomme RM and Hendriks T: Plasma gelatinase activity does not reflect disease activity after operation for colorectal cancer. Oncology 68: 256-262, 2005.
22. Stearns ME, Rhim J and Wang M: Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 5: 189-196, 1999.
23. Siwik DA, Chang DL and Colucci WS: Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 86: 1259-1265, 2000.
24. Shi Y, Inoue S, Shinozaki R, Fukue K and Kougo T: Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro. Jpn J Cancer Res 89: 757-767, 1998.
25. De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E and Catalane G: Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 117: 365-373, 2000.
26. Jung K, Laube C, Lein M, Lichtinghagen R, Tschesche H, Schnorr D and Loening SA: Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin Chem 44: 1060-1062, 1998.
27. Jung K, Gerlach R and Tanus-Santos JE: Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases. Clin Chim Acta 373: 180-181, 2006.